Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival

Glioblastoma (GBM) is the most malignant brain tumor where patients' survival is only 14.6 months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and radiotherapy. There is an urgent, unmet need for novel, effective therapeutic strategies for this devastating disease...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Poli, Aurélie, Wang, Jian, Domingues, Olivia, Planagumà, Jesús, Yan, Tao, Rygh, Cecilie Brekke, Skaftnesmo, Kai Ove, Thorsen, Frits, McCormack, Emmet, Hentges, François, Pedersen, Paal Henning, Zimmer, Jacques, Enger, Per Øyvind, Chekenya, Martha
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2013
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3824525/
https://ncbi.nlm.nih.gov/pubmed/24127551
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares